Cite

    Dirk Schadendorf et al.. “Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.” European journal of cancer, vol. 82, 2017, pp. 45–55. http://access.bl.uk/ark:/81055/vdc_100047869267.0x00000f